Showing 3501-3510 of 7422 results for "".
- Mustela Introduces Skin-Soothing PJs for Eczema-Prone Babies and Toddlershttps://practicaldermatology.com/news/mustela-introduces-skin-soothing-pjs-for-eczema-prone-babies-and-toddlers/2459885/The Global Wellness Institute recently cited smart and healing fashion as one of the biggest trends in wellness, and the new Mustela
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce
- Physician Burnout Rates Fall Modestlyhttps://practicaldermatology.com/news/physician-burnout-rates-fall-modestly/2459892/The burnout rate among physicians in the United States has dropped, but there remains significant room for improvement, new data suggest. The burnout rate dropped modestly in 2017 from its peak in 2014. Current burnout rates are in line with 2011 levels. The triennial s
- Dermatology Drugs Market to Reach $34.5 Billion by 2023https://practicaldermatology.com/news/dermatology-drugs-market-to-reach-345-billion-by-2023/2459895/The dermatology drugs market is expected to reach $34.5 billion by 2023, a new report suggests. Research and Markets says that, among
- Stelatopia Emollient Face Cream Now Available from Mustelahttps://practicaldermatology.com/news/stelatopia-emollient-face-cream-now-available-from-mustela/2459902/Mustela Stelatopia Emollient Face Cream is now available, specifically designed for extremely dry to eczema-prone skin and gentle enough to use on newborns. Formulated with Avocado Perseose®, which is intended to restore and protect the skin barrier by boosting ceramides a
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- MedPharm Ltd. Expands Partnership with Palvella Therapeutics, Inc. for PC Treatmenthttps://practicaldermatology.com/news/medpharm-ltd-expands-partnership-with-palvella-therapeutics-inc-for-pc-treatment/2459906/MedPharm Ltd, is expanding its partnership with Palvella Therapeutics, Inc. MedPharm has employed its formulation expertise to support Palvella’s development of a novel,
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topa
- Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meetinghttps://practicaldermatology.com/news/dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting/2459916/Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washing
- Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meetinghttps://practicaldermatology.com/news/menlo-therapeutics-to-present-late-breaking-oral-presentation-at-aad-annual-meeting/2459917/Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. The ab